Get the Stockscreener App
228.87
0.53%
1.20
After Hours:
228.87
Beigene Ltd Adr Stock (ONC) Latest News
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene director Wang Xiaodong sells $7.37 million in shares - Investing.com
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene announces passing of board member Donald Glazer - Investing.com
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene executive sells over $1.1m in company shares - Investing.com
JMP calls BeiGene a 'unique investment opportunity', sets $288 shares target By Investing.com - Investing.com
CCBI Lowers BEIGENE (06160.HK) TP to $140, Solid 2Q Results Expected - AASTOCKS.com
Nomura Raises BEIGENE (06160.HK)'s TP to $158.37 and Rev. Forecast for FY24/FY25 - AASTOCKS.com
BeiGene CFO sells over $145,000 in company stock - Investing.com
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why - Yahoo Finance
BofA raises BeiGene stock target to $179.30 on strong drug sales growth - Investing.com
Primecap Odyssey Funds' 2023 Semiannual Letter - GuruFocus.com
7 Best Cancer Stocks To Invest In Now - Barchart
BEIGENE On Reported 'Brukinsa' Infringement: To React when Appropriate with Vigorous Defense - AASTOCKS.com
BEIGENE Collapses 13% to Half-Yr Low With High Vol., as its Blood Cancer Drug 'Brukinsa' Get Sued for Infringement - AASTOCKS.com
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Making it harder to "buy" China, Inc. - US-China Institute
What Happens to Your ETFs if Chinese ADRs Delist? - HK.Morningstar.com
Will We See a Slew of ADR Delistings? - HK.Morningstar.com
See What the Public Investment Fund Bought Recently Including Walmart and FedEx Stocks - Sovereign Wealth Fund Institute
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion - Yahoo Finance
BeiGene Ltd. Sponsored ADR to Host Earnings Call - AccessWire
BeiGene: Recent Sector Weakness Offers An Attractive Entry Point (NASDAQ:ONC) - Seeking Alpha
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):